

# Brian Agan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4844000/publications.pdf>

Version: 2024-02-01

159  
papers

7,556  
citations

81900

39  
h-index

56724

83  
g-index

167  
all docs

167  
docs citations

167  
times ranked

10102  
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding “Hybrid Immunity” Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	5.8	23
2	The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity. <i>Clinical Infectious Diseases</i> , 2022, 74, 897-900.	5.8	24
3	Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States. <i>Scientific Reports</i> , 2022, 12, 1196.	3.3	3
4	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	12.4	75
5	Anatomical Site, Viral Ribonucleic Acid Abundance, and Time of Sampling Correlate With Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 During Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab623.	0.9	0
6	COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	4
7	An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
8	Ophthalmic Disease Prevalence and Incidence among People Living with Human Immunodeficiency Virus in the AFRICOS Study. <i>Ophthalmology</i> , 2021, 128, 1104-1107.	5.2	0
9	Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV. <i>Military Medicine</i> , 2021, 186, 279-285.	0.8	4
10	Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab076.	0.9	3
11	2021 update to HIV-TREPS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1898-1906.	3.0	1
12	Effects of human immunodeficiency virus status on symptom severity in influenza-like illness in an otherwise healthy adult outpatient cohort. <i>Journal of Investigative Medicine</i> , 2021, 69, 1230-1237.	1.6	0
13	Factors associated with erectile dysfunction diagnosis in men with HIV infection: a case-control study. <i>HIV Medicine</i> , 2021, 22, 617-622.	2.2	1
14	Association between depression and HIV treatment outcomes in a US military population with HIV infection. <i>AIDS Research and Therapy</i> , 2021, 18, 29.	1.7	8
15	Clinical, Immunological, and Virological SARS-CoV-2 Phenotypes in Obese and Nonobese Military Health System Beneficiaries. <i>Journal of Infectious Diseases</i> , 2021, 224, 1462-1472.	4.0	14
16	Predictive Value of an Age-Based Modification of the National Early Warning System in Hospitalized Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab421.	0.9	4
17	Prospective Evaluation of an Abbreviated Test Battery to Screen for Neurocognitive Impairment in HIV-Positive Military Members. <i>AIDS and Behavior</i> , 2021, 25, 3347-3354.	2.7	0
18	Immunologic resilience and COVID-19 survival advantage. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1176-1191.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study. <i>HIV Medicine</i> , 2021, , .	2.2	1
20	Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab517.	0.9	16
21	COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab556.	0.9	16
22	Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. <i>Clinical Infectious Diseases</i> , 2020, 71, 652-660.	5.8	44
23	CD4 rate of increase is preferred to CD4 threshold for predicting outcomes among virologically suppressed HIV-infected adults on antiretroviral therapy. <i>PLoS ONE</i> , 2020, 15, e0227124.	2.5	14
24	Noncommunicable Diseases: Yet Another Challenge for Human Immunodeficiency Virus Treatment and Care in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2020, 71, 1874-1876.	5.8	6
25	Multidrug-Resistant Organisms from Ophthalmic Cultures: Antibiotic Resistance and Visual Acuity. <i>Military Medicine</i> , 2020, 185, e1002-e1007.	0.8	4
26	HIV Care Continuum and Meeting 90-90-90 Targets: Cascade of Care Analyses of a U.S. Military Cohort. <i>Military Medicine</i> , 2020, 185, e1147-e1154.	0.8	6
27	The Intersection of HIV, Diabetes, and Race: Exploring Disparities in Diabetes Care among People Living with HIV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822090424.	1.5	6
28	Predictors of health-related quality of life among military HIV-infected individuals. <i>Quality of Life Research</i> , 2020, 29, 1855-1869.	3.1	7
29	Antiretroviral Therapy and Viral Suppression Among Active Duty Service Members with Incident HIV Infection â€” United States, January 2012â€”June 2018. <i>Morbidity and Mortality Weekly Report</i> , 2020, 69, 366-370.	15.1	3
30	Sexual Risk Behaviors Associated with Sexually Transmitted Infections in a US Military Population Living with HIV After the Repeal of â€œDon't Ask, Don't Tellâ€œ. <i>AIDS Patient Care and STDs</i> , 2020, 34, 523-533.	2.5	1
31	Refractive surgery in the HIV-positive U.S. Military Natural History Study Cohort: complications and risk factors. <i>Journal of Cataract and Refractive Surgery</i> , 2019, 45, 1612-1618.	1.5	1
32	Age, Race, and At-Risk Drinking in an HIV-infected U.S. Military Cohort. <i>Military Medicine</i> , 2019, 184, e263-e267.	0.8	4
33	Posttraumatic Stress Disorder and Neurocognitive Impairment in a U.S. Military Cohort of Persons Living with HIV. <i>Psychiatry (New York)</i> , 2019, 82, 1-12.	0.7	2
34	Extragenital chlamydia infection among active-duty women in the United States Navy. <i>Military Medical Research</i> , 2019, 6, 3.	3.4	5
35	Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure. <i>Clinical Infectious Diseases</i> , 2019, 69, 2145-2152.	5.8	62
36	336. Disparities in Cardiovascular Disease Prevention Among Persons Living with HIV in the United States Military Natural History Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S178-S179.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Biomedical Response to <i>Neisseria gonorrhoeae</i> and Other Sexually Transmitted Infections in the US Military. <i>Military Medicine</i> , 2019, 184, 51-58.	0.8	2
38	The US Military HIV Natural History Study: Informing Military HIV Care and Policy for Over 30 Years. <i>Military Medicine</i> , 2019, 184, 6-17.	0.8	8
39	Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population. <i>Clinical Infectious Diseases</i> , 2019, 69, 155-158.	5.8	9
40	Effect of HIV infection and antiretroviral therapy on immune cellular functions. <i>JCI Insight</i> , 2019, 4, .	5.0	70
41	Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 502-506.	2.1	4
42	2248. Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort. <i>Open Forum Infectious Diseases</i> , 2018, 5, S665-S665.	0.9	3
43	602. Factors Associated With Erectile Dysfunction Diagnosis in HIV-Infected Individuals: A Caseâ€“Control Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S220-S221.	0.9	0
44	Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons. <i>AIDS Research and Therapy</i> , 2018, 15, 25.	1.7	2
45	Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 107.	2.4	15
46	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2186-2196.	3.0	4
47	Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals. <i>Vaccine</i> , 2017, 35, 6103-6111.	3.8	2
48	Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 364-369.	2.1	14
49	Health-related quality of life among military HIV patients on antiretroviral therapy. <i>PLoS ONE</i> , 2017, 12, e0178953.	2.5	21
50	P3.68â€“...Disparity among ethnic race groups in sexual transmitted infection for lifestyle variables of male and female active duty military personnel. , 2017, , .		0
51	Lower Baseline Germinal Center Activity and Preserved Th1 Immunity are Associated with Hepatitis B Vaccine Response in Treated HIV Infection. <i>Pathogens and Immunity</i> , 2017, 2, 66.	3.1	12
52	Regimen Switching After Initial Haart By Race in a Military Cohort. <i>Open Public Health Journal</i> , 2017, 10, 195-207.	0.4	0
53	Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20524.	3.0	25
54	Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 605.	2.6	6

#	ARTICLE	IF	CITATIONS
55	MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity. PLoS Pathogens, 2016, 12, e1005580.	4.7	22
56	Baseline Albumin/Globulin Ratio Predicted Progression to AIDS Among Persons with Stage 1 HIV Disease in the Pre-Combination Antiretroviral Therapy Era. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
57	Do Low Vitamin D Levels Explain Poorer Influenza Vaccine Immunogenicity Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Adults?. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
58	Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infectious Diseases, 2016, 16, 351.	2.9	11
59	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	2.2	21
60	Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults. Vaccine, 2016, 34, 5040-5046.	3.8	10
61	Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. AIDS Research and Human Retroviruses, 2016, 32, 1187-1197.	1.1	1
62	Relationship of Albumin/Globulin Ratio With Biomarkers of Inflammation and Coagulation in HIV-Infected Persons Before and After Combination Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
63	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	3.0	7
64	Factors associated with HIV viral load blips and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. AIDS Research and Therapy, 2016, 13, 16.	1.7	23
65	Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy. Alcoholism: Clinical and Experimental Research, 2016, 40, 529-535.	2.4	30
66	Toxoplasma gondii seroprevalence: 30-year trend in an HIV-infected US military cohort. Diagnostic Microbiology and Infectious Disease, 2016, 84, 34-35.	1.8	6
67	Parametric cost-effectiveness inference with skewed data. Computational Statistics and Data Analysis, 2016, 94, 210-220.	1.2	5
68	D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS ONE, 2016, 11, e0152588.	2.5	50
69	The Association between Sexually Transmitted Infections, Length of Service and Other Demographic Factors in the U.S. Military. PLoS ONE, 2016, 11, e0167892.	2.5	17
70	Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia. BMC Research Notes, 2015, 8, 595.	1.4	17
71	HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Medicine, 2015, 16, 161-167.	2.2	16
72	Seroprevalence and Seroincidence of Herpes Simplex Virus (2006-2010), Syphilis (2006-2010), and Vaccine-Preventable Human Papillomavirus Subtypes (2000-2010) Among US Military Personnel. Sexually Transmitted Diseases, 2015, 42, 253-258.	1.7	13

#	ARTICLE	IF	CITATIONS
73	Randomized, Double-Blind, Placebo-Controlled Study on Decolonization Procedures for Methicillin-Resistant Staphylococcus aureus (MRSA) among HIV-Infected Adults. PLoS ONE, 2015, 10, e0128071.	2.5	15
74	Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Research and Human Retroviruses, 2015, 31, 514-518.	1.1	5
75	Reply to Yang et al. Clinical Infectious Diseases, 2015, 60, 1444-1445.	5.8	0
76	Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus-Infected Individuals. JAMA Internal Medicine, 2015, 175, 88.	5.1	69
77	A Single Dose of Benzathine Penicillin G Is as Effective as Multiple Doses of Benzathine Penicillin G for the Treatment of HIV-Infected Persons With Early Syphilis. Clinical Infectious Diseases, 2015, 60, 653-660.	5.8	40
78	Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons. Open Forum Infectious Diseases, 2015, 2, ofv034.	0.9	8
79	Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons. BMC Infectious Diseases, 2015, 15, 203.	2.9	2
80	Inference for Surrogate Endpoint Validation in the Binary Case. Journal of Biopharmaceutical Statistics, 2015, 25, 1272-1284.	0.8	1
81	HIV Outcomes in Hepatitis B Virus Coinfected Individuals on HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 197-205.	2.1	47
82	Combining Epidemiologic and Biostatistical Tools to Enhance Variable Selection in HIV Cohort Analyses. PLoS ONE, 2014, 9, e87352.	2.5	11
83	HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function. Current HIV Research, 2014, 12, 50-59.	0.5	14
84	1561The Relationship Between Self-reported Adherence and Efavirenz Blood Levels on the Appearance of HIV Viral Load Blips. Open Forum Infectious Diseases, 2014, 1, S415-S415.	0.9	0
85	1566Factors Associated with 10 Years of Continuous HIV Viral Load Suppression on HAART. Open Forum Infectious Diseases, 2014, 1, S417-S417.	0.9	0
86	Race/ethnicity and HAART initiation in a military HIV infected cohort. AIDS Research and Therapy, 2014, 11, 10.	1.7	5
87	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110.	3.0	13
88	Delayed-type hypersensitivity (DTH) test energy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy. Journal of the International AIDS Society, 2014, 17, 18799.	3.0	5
89	The VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 226-230.	2.1	33
90	Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers. PLoS ONE, 2014, 9, e105591.	2.5	9

#	ARTICLE	IF	CITATIONS
91	Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. <i>Neurology</i> , 2013, 80, 371-379.	1.1	77
92	Expanded Sexually Transmitted Infection Surveillance Efforts in the United States Military: A Time for Action. <i>Military Medicine</i> , 2013, 178, 1271-1280.	0.8	10
93	Reply to Tsai et al. <i>Journal of Infectious Diseases</i> , 2013, 208, 1186-1186.	4.0	0
94	A Comparison of HAART Outcomes between the US Military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS). <i>PLoS ONE</i> , 2013, 8, e62273.	2.5	16
95	Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service. <i>Msmr</i> , 2013, 20, 21-4.	0.1	4
96	Gonorrhoea or chlamydia in a US military HIV-positive cohort. <i>Sexually Transmitted Infections</i> , 2012, 88, 266-271.	1.9	22
97	Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 185-193.	4.0	108
98	Results of a 25-Year Longitudinal Analysis of the Serologic Incidence of Syphilis in a Cohort of HIV-Infected Patients With Unrestricted Access to Care. <i>Sexually Transmitted Diseases</i> , 2012, 39, 440-448.	1.7	29
99	Prevalence and Factors Associated With Sleep Disturbances Among Early-Treated HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2012, 54, 1485-1494.	5.8	74
100	Hepatitis B Vaccine Antibody Response and the Risk of Clinical AIDS or Death. <i>PLoS ONE</i> , 2012, 7, e33488.	2.5	11
101	Hepatitis E Virus Infection in HIV-infected Persons. <i>Emerging Infectious Diseases</i> , 2012, 18, 502-506.	4.3	67
102	Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort. <i>AIDS Research and Therapy</i> , 2012, 9, 4.	1.7	9
103	Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort. <i>PLoS ONE</i> , 2012, 7, e47310.	2.5	27
104	Early Postseroconversion CD4 Cell Counts Independently Predict CD4 Cell Count Recovery in HIV-1-Positive Subjects Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 387-395.	2.1	21
105	Elevated CD8 Counts During HAART Are Associated With HIV Virologic Treatment Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 396-403.	2.1	23
106	Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS. <i>PLoS ONE</i> , 2011, 6, e17956.	2.5	48
107	Risk Factors Influencing Antibody Responses to Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Antigens in Patients Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 83-90.	2.1	23
108	Medical Encounter Characteristics of HIV Seroconverters in the US Army and Air Force, 2000-2004. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 372-380.	2.1	10

#	ARTICLE	IF	CITATIONS
109	Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. <i>AIDS Research and Therapy</i> , 2011, 8, 2.	1.7	32
110	Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2011, 203, 1815-1823.	4.0	57
111	The Timing of Hepatitis B Virus (HBV) Immunization Relative to Human Immunodeficiency Virus (HIV) Diagnosis and the Risk of HBV Infection Following HIV Diagnosis. <i>American Journal of Epidemiology</i> , 2011, 173, 84-93.	3.4	17
112	Association of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Colonization With High-Risk Sexual Behaviors in Persons Infected With Human Immunodeficiency Virus (HIV). <i>Medicine (United States)</i> , 2011, 90, 1010-1016.	1.0	10
113	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience. <i>AIDS Patient Care and STDs</i> , 2011, 25, 29-36.	2.5	20
114	Impact of Weight on Immune Cell Counts among HIV-Infected Persons. <i>Vaccine Journal</i> , 2011, 18, 940-946.	3.1	40
115	Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?. <i>Aids</i> , 2010, 24, 2881-2883.	2.2	26
116	Are HIV-Positive Persons Progressing Faster After Diagnosis Over the Epidemic?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, e6-e7.	2.1	7
117	Obesity among HIV-infected persons: impact of weight on CD4 cell count. <i>Aids</i> , 2010, 24, 1069-1072.	2.2	53
118	Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. <i>Aids</i> , 2010, 24, 535-543.	2.2	172
119	Trends and Causes of Hospitalizations Among HIV-Infected Persons During the Late HAART Era: What Is the Impact of CD4 Counts and HAART Use?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 248-257.	2.1	92
120	Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. <i>AIDS Research and Therapy</i> , 2010, 7, 14.	1.7	73
121	CD4 T Cell Count Reconstitution in HIV Controllers after Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 50, 1187-1191.	5.8	36
122	HIV Infection Among U.S. Army and Air Force Military Personnel: Sociodemographic and Genotyping Analysis. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 889-894.	1.1	13
123	Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years. <i>Clinical Infectious Diseases</i> , 2010, 50, 426-436.	5.8	66
124	Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. <i>Aids</i> , 2010, 24, 545-555.	2.2	38
125	The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. <i>Vaccine</i> , 2010, 28, 7583-7588.	3.8	9
126	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	12.6	1,054



#	ARTICLE	IF	CITATIONS
127	A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Conjugate Vaccine to Polysaccharide Vaccine among HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2010, 202, 1114-1125.	4.0	76
128	The Effect of Human Immunodeficiency Virus on Hepatitis B Virus Serologic Status in Co-Infected Adults. <i>PLoS ONE</i> , 2010, 5, e8687.	2.5	27
129	Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic. <i>PLoS ONE</i> , 2010, 5, e10106.	2.5	202
130	Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long-Term Nonprogressors in the US Department of Defense HIV Natural History Study. <i>Journal of Infectious Diseases</i> , 2009, 200, 1714-1723.	4.0	268
131	Responsiveness of T Cells to Interleukin-7 Is Associated with Higher CD4+T Cell Counts in HIV-1-Positive Individuals with Highly Active Antiretroviral Therapy-Induced Viral Load Suppression. <i>Journal of Infectious Diseases</i> , 2009, 199, 1872-1882.	4.0	46
132	Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 574-580.	2.1	65
133	Cutaneous Malignancies Among HIV-Infected Persons. <i>Archives of Internal Medicine</i> , 2009, 169, 1130.	3.8	51
134	Is HIV Becoming More Virulent? Initial CD4 Cell Counts among HIV Seroconverters during the Course of the HIV Epidemic: 1985-2007. <i>Clinical Infectious Diseases</i> , 2009, 48, 1285-1292.	5.8	33
135	Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count. <i>Vaccine</i> , 2009, 27, 4731-4738.	3.8	73
136	Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. <i>Aids</i> , 2009, 23, 41-50.	2.2	232
137	Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors' reply. <i>Aids</i> , 2009, 23, 1791-1792.	2.2	13
138	The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 305-309.	2.1	20
139	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. <i>Nature Medicine</i> , 2008, 14, 413-420.	30.7	118
140	Duffy Antigen Receptor for Chemokines Mediates trans-Infection of HIV-1 from Red Blood Cells to Target Cells and Affects HIV-AIDS Susceptibility. <i>Cell Host and Microbe</i> , 2008, 4, 52-62.	11.0	166
141	Independent Effects of Genetic Variations in Mannose-Binding Lectin Influence the Course of HIV Disease: The Advantage of Heterozygosity for Coding Mutations. <i>Journal of Infectious Diseases</i> , 2008, 198, 72-80.	4.0	31
142	Increasing Age at HIV Seroconversion From 18 to 40 Years Is Associated With Favorable Virologic and Immunologic Responses to HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 40-47.	2.1	50
143	Apolipoprotein (apo) E4 enhances HIV-1 cell entry <i>in vitro</i> , and the APOE $\epsilon$ 4/ $\epsilon$ 4 genotype accelerates HIV disease progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8718-8723.	7.1	181
144	CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2008, 3, e3165.	2.5	23

#	ARTICLE	IF	CITATIONS
145	Role of CCL3L1-CCR5 Genotypes in the Epidemic Spread of HIV-1 and Evaluation of Vaccine Efficacy. PLoS ONE, 2008, 3, e3671.	2.5	23
146	HIV-1 Disease-Influencing Effects Associated with ZNRD1, HCP5 and HLA-C Alleles Are Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles. PLoS ONE, 2008, 3, e3636.	2.5	70
147	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	14.5	152
148	Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Research, 2006, 16, 527-535.	5.5	130
149	Effectiveness of highly-active antiretroviral therapy by race/ethnicity. Aids, 2006, 20, 1531-1538.	2.2	43
150	Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 194-200.	2.1	442
151	Sensitivity of the Multispot HIV-1/HIV-2 Rapid Test Using Samples from Human Immunodeficiency Virus Type 1-Positive Individuals with Various Levels of Exposure to Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology, 2006, 44, 1831-1833.	3.9	20
152	Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer, 2005, 104, 1505-1511.	4.1	212
153	History of U.S. Military Contributions to the Study of Bacterial Zoonoses. Military Medicine, 2005, 170, 39-48.	0.8	21
154	Azithromycin Might Not Protect Against Treponema pallidum Infection or Reactivation in HIV Type 1-Infected Patients. Clinical Infectious Diseases, 2005, 41, 420-420.	5.8	3
155	The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility. Science, 2005, 307, 1434-1440.	12.6	1,040
156	Potential Use of Microarray Technology for Rapid Identification of Central Nervous System Pathogens. Military Medicine, 2004, 169, 594-599.	0.8	8
157	Unintended Smallpox Vaccination of HIV-1-Infected Individuals in the United States Military. Clinical Infectious Diseases, 2004, 38, 1320-1322.	5.8	29
158	Pulmonary Hemorrhage Syndrome Associated with an Autochthonous Case of Dengue Hemorrhagic Fever. Southern Medical Journal, 2004, 97, 688-691.	0.7	29
159	Laboratory diagnosis of Bartonella infections. Clinics in Laboratory Medicine, 2002, 22, 937-962.	1.4	77